Abstract:Hutchinson-Gilford progeria syndrome (HGPS or progeria) is typically caused by a dominant-negative C•G-to-T•A mutation (c.1824 C>T; p.G608G) in LMNA, the gene that encodes nuclear lamin A. This mutation causes RNA mis-splicing that produces progerin, a toxic protein that induces rapid ageing and shortens the lifespan of children with progeria to approximately 14 years1-4. Adenine base editors (ABEs) convert targeted A•T base pairs to G•C base pairs with minimal by-products and without requiring double-strand DNA breaks or donor DNA templates5,6. Here we describe the use of an ABE to directly correct the pathogenic HGPS mutation in cultured fibroblasts derived from children with progeria and in a mouse model of HGPS. Lentiviral delivery of the ABE to fibroblasts from children with HGPS resulted in 87-91% correction of the pathogenic allele, mitigation of RNA mis-splicing, reduced levels of progerin and correction of nuclear abnormalities. Unbiased off-target DNA and RNA editing analysis did not detect off-target editing in treated patient-derived fibroblasts. In transgenic mice that are homozygous for the human LMNA c.1824 C>T allele, a single retro-orbital injection of adeno-associated virus 9 (AAV9) encoding the ABE resulted in substantial, durable correction of the pathogenic mutation (around 20-60% across various organs six months after injection), restoration of normal RNA splicing and reduction of progerin protein levels. In vivo base editing rescued the vascular pathology of the mice, preserving vascular smooth muscle cell counts and preventing adventitial fibrosis. A single injection of ABE-expressing AAV9 at postnatal day 14 improved vitality and greatly extended the median lifespan of the mice from 215 to 510 days. These findings demonstrate the potential of in vivo base editing as a possible treatment for HGPS and other genetic diseases by directly correcting their root cause.

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice

Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse

Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy

In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice

Adenine Base Editing in an Adult Mouse Model of Tyrosinaemia

In Vivo Base Editing Rescues Hutchinson–Gilford Progeria Syndrome in Mice

Correction of Diverse Muscular Dystrophy Mutations in Human Engineered Heart Muscle by Single-Site Genome Editing

Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy

Effective Gene Editing by High-Fidelity Base Editor 2 in Mouse Zygotes

Correction of a pathogenic gene mutation in human embryos

Engineering precise adenine base editor with infinitesimal rates of bystander mutations and off-target editing

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Decreasing predictable DNA off-target effects and narrowing editing windows of adenine base editors by fusing human Rad18 protein variant

Human Cell Based Directed Evolution of Adenine Base Editors with Improved Efficiency

Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease

A precise and efficient adenine base editor